Skinbiotherapeutics Share Discussion Threads

[bobalot] 12/10/2017 14:07

At least the share price bounces off the lower support floor.

[onedayrodders] 12/10/2017 13:50

I don't think it's a question of hearing .. just like OPTI, today's AIM only wants to see hard cash, no longer do SP's run up on excitement and potential alone, even important milestones are ignored.

Unless we get some news from left field here, our best short term chances are to ride the coat tails of revenue news from OPTI which should mean sentiment and confidence here will improve and share price advances will find a higher support level.

[bobalot] 12/10/2017 13:23

No problem, there is a long pipeline of news flow in the coming weeks and months, even the tone deaf will get the message --- lol.

[onedayrodders] 12/10/2017 12:44

it appears no one's listening bobalot

[bobalot] 11/10/2017 14:25

Here's a recap on last weeks announcement --- it shows the business has a lot of potential.

Scientific update

As outlined at IPO in April 2017, SkinBioTherapeutics has been concentrating on further developing its technology towards the three applications in skin care, anti-infection and skin repair.

The positive cytotoxicity result above is a key milestone. However, other work is progressing well and the Company has summarised this below:

-     Manufacture: work on scale-up has been initiated, confirmed by the successful manufacture of SkinBiotix® ;by an external partner

-     Pilot scale formulation has been initiated by an external partner with expertise in cosmetic formulation development. Phase one of three is complete; testing of solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway

-     Early stage commercial discussions are ongoing with both potential manufacturing partners as well as potential licensees

-      Anti-infection and eczema programmes

o  A 'time-course' study, has confirmed that the frequency of application required for protection is three times daily. Therefore, protection against Staphylococcus aureus infection for both eczema and infection programmes requires application every five hours*

-      Regulatory process has commenced and a regulatory consultant has been appointed 

-      Ongoing scientific studies:

o Defining dosage is complete - for all three applications. SkinBioTherapeutics has finalised a dosing level at which the technology will be used which maintains the viability of the skin cells

o  Confirmation of the modifying property of SkinBiotix® ;on protein composition of the skin, increasing the expression of Claudin 4, an essential component in tight junctions which are critical for the barrier characteristic of skin

*These data were recently presented at a Wellcome Trust conference: "Host Microbiome Interactions in Health and Disease".

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"This announcement demonstrates the excellent progress SkinBioTherapeutics is making at all levels - scientific, development, manufacture and commercial.

"The result from the cytotoxicity testing by Charles River is essential external validation of our SkinBiotix® ;platform.  This was one of the key milestones to pass and was highlighted as such at the IPO. Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies.

"Operationally, we are on track. The development programmes are progressing well, we are generating further scientific data on SkinBiotix® ;confirming its suitability for application to skin, and industry awareness of our technology is growing."

[slartybartfaster] 11/10/2017 14:11

Based on what?
These tops ups are great if you have the funds, freaking painfully annoying when not. Sick to death of this range bound bs and wanna be traders.

[onedayrodders] 11/10/2017 13:07

yet ANOTHER top up opportunity .. never ending

[bobalot] 11/10/2017 11:45

By that time the share price might be in the 50p - 60p range as a guesstimate.

[pglancy] 10/10/2017 16:22

De risked after the human trials and a commercial agreement in place.

[elrico] 10/10/2017 11:43

Vanduke - I enjoy the researching aspect of both companies, especially OPTI because there are so many facets to it. There's no emotion attachment, period.

Myself and Bob were having a cordial exchange of views. If you have problem with this, then use the filter option.

I would have thought you would have learned from your last advisory to me.

I'll leave you to your emotional attachment to your so called syndicate and inform us mere mortals your accumulating.

No offence, but I'm filtering you because it is best for this BB.

[bobalot] 10/10/2017 09:18

The prospects for SkinBio have improved considerably, since the health and safety approval it has been effectively derisked after passing that key milestone.

[vanduke] 10/10/2017 08:13

Elrico, no offence intended please. Your last post and posts here are an example of your emotional attachment to OPTI and now SBTX. Step back for a while or you will loose all objectivity.

[elrico] 09/10/2017 22:57

Shrewdmole - leave what? I don't believe me and Bob (or Rita or Sue) are arguing. We are just bouncing ideas on news. We have a difference of timelines on news and I asked him about leakynews. He answered and I dropped it.

No idea what you mean about the last sentence.

[shrewdmole] 09/10/2017 22:38

Guys why the arguing even it appears in a situation where both of you are holders and positive about the future?

Elrico

Leave it mate it is a no win situation.

I had it on Opti bb and you will not win.

S

[vanduke] 09/10/2017 20:43

Accumulating here..

[bobalot] 09/10/2017 17:07

After following OPTI for a number of years the leaky news often came from TW sources.

The SkinBio share price has huge growth opportunities coming investors way over the next twelve months imo; which is a very attractive fact.

[elrico] 09/10/2017 16:38

Bob - I think you will find it difficult to find any OPTI investor argue against your assertion "SBTX is going to be a multibagger" But not for a while just yet. However, your accusation of leakynews (OPTI) is unfounded. Please show us an example of RNSable leakynews.

I agree the other observation that the share price oscillates...very few don't, especially when news is pending. Currently, OPTI is a traders dream. However, I am not a trader of OPTI but a LTI happy to watch progress over the next few years...assuming nothing nasty materialises of course.

Ref SBTX shares. A recent application to cancel blocks of OPTI shares at Manchester's chancery has established progress, amounting nothing more than tidying up the share registry in readiness for the in-specie divi. The expiry date for any appeal against cancelling certain right to shares is 23rd October.

[bobalot] 09/10/2017 16:30

The company have made a lot of progress including commercial discussions.


Q2: Now, you also provided a scientific update to the market, what were the key points that investors should take from that?


A2: I think it’s more an operational update really, it’s not just a scientific update, we’ve actually been making progress across the board really.

So, in terms of the science, we’ve now shown that our SkinBiotix technology, we’ve shown the doses at which it needs to be applied for all three of our programmes, which if you remember are a cosmetic programme, an infection programme and an eczema programme, so we’ve defined doses for those.

We’ve also done a timed course in respect of the infection programme so we know how often we’d have to treat the skin now for full effect.

Other areas where we’ve made a lot of progress are the manufacture scale up so, of course, we need scale up because we need to be able to make our product in larger amounts so we’ve made some headway with that.

We’ve also started formulation work so making progress right across the board really and there are even some early commercial discussions underway too.

[bobalot] 09/10/2017 16:21

SkinBio is going to be a multi-bagger --- OPTI is a good investment but it oscillates too much on a drip feed of news snippets that leak out.

SBTX has a strong pipeline of news coming our way.

SBTX will pass the clinical cream to a major brand name after clinical testing which is likely to only take three months followed by plenty of other human testing for the other products.

This stock is highly likely to reach 50-60p just like Opti did imo. But don't expect OPTI to give away free shares in SkinBio any time soon as a dividend.

[elrico] 09/10/2017 16:09

Bob - pump and dump or not, I fail to see why you expect "SkinBio will have far better returns after clinical testing early next year." It appears you be the kettle calling someone black ass. The fact is OPTI have far more news in the pipeline in the VERY NEAR TERM, while SBTX has nothing (as far as I'm expecting) in the news pipeline until 2018. I hope I'm wrong as hold a nice chunk of SBTX and expect this to double again once OPTI release my share....whenever that may be.

[bobalot] 09/10/2017 15:14

In other words all three products are approved for use by humans --- which is an enormous step forward.

[trotterstrading] 09/10/2017 14:57

The Important part is the fact they have passed INDEPENDENT cytotoxicity. If we get independent proof of efficacy during human patient trials (in line with human skin results performed in the lab) then we are sitting on a goldmine. 3 multi billion markets and unmet medical need!

[bobalot] 09/10/2017 14:28

The 18 patents are now worth a lot more after passing health and safety.

[shrewdmole] 09/10/2017 14:14

Does soh have a twin sister?

Very clear very understated.

S

[bobalot] 09/10/2017 13:33

A really useful Q&A session --- early commercial discussions + product development.

Skinbiotherapeutics PLC Q&A: Passing Cytotoxicity Tests & Scientific Update (LON:SBTX)
Posted by: Amilia Stone 6th October 2017

Skinbiotherapeutics PLC (LON:SBTX) Chief Executive Officer Dr. Catherine O’Neill caught up with DirectorsTalk for an exclusive interview to discuss passing third party cytotoxicity tests, their scientific update to the market & what’s next for the company
 
Q1: We saw this morning that the company has passed 3rd party cellular toxicity tests, can you tell me what was involved and what this means for Skinbiotherapeutics?
A1: So, basically this is the first key milestone that we set out in our IPO so passing cytotoxicity is very very important. These tests are to be run by a third party and the tests are necessary before we can take our programme actually into human trials so the fact that we’ve been passed them is very good.
 
Q2: Now, you also provided a scientific update to the market, what were the key points that investors should take from that?
A2: I think it’s more an operational update really, it’s not just a scientific update, we’ve actually been making progress across the board really.
So, in terms of the science, we’ve now shown that our SkinBiotix technology, we’ve shown the doses at which it needs to be applied for all three of our programmes, which if you remember are a cosmetic programme, an infection programme and an eczema programme, so we’ve defined doses for those. We’ve also done a timed course in respect of the infection programme so we know how often we’d have to treat the skin now for full effect.
Other areas where we’ve made a lot of progress are the manufacture scale up so, of course, we need scale up because we need to be able to make our product in larger amounts so we’ve made some headway with that. We’ve also started formulation work so making progress right across the board really and there are even some early commercial discussions underway too.
 
Q3: This is the first announcement that you’ve made since IPO in April, there seems quite a bit of news here?
A3: Yes, what we wanted to do on the back of cytotoxicity results, which of course are a material set of data, we wanted to give the market a full update really of what we have been doing and when we give an update we want it to be robust and of material value so hopefully, that’s what we’ve achieved today.
 
Q4: So, what is next for Skinbiotherapeutics, what should investors be looking out for in terms of news flow?
A4: I think it’s a very exciting time, both for our company and also for the skin microbiome sector as a whole so just a couple of weeks ago, I was at a scientific conference, a Wellcome Trust-funded conference, looking at the microbiome and how it interreacts with humans so this whole area is vibrant.

Specifically, for Skinbiotherapeutics, on Thursday of this week we’ve got our maiden final year results being issued so we’ll maybe be speaking again! Also, we’re continuing now preparing for the initial human study and, as I said, moving forward the early-stage commercial discussions but it’s important to stress that these are early-days.
For the sector as a whole, as I’ve suggested, the area is gaining a very increasing level of interest and attention so I think exciting times ahead of us, yes.

www.directorstalkinterviews.com/skinbiotherapeutics-plc-qa-passing-cytotoxicity-tests-scientific-update-lonsbtx/412737666